Daily Ards Research Analysis
Among today's ARDS-focused papers, a national cohort study found no outcome advantage with continuous rocuronium in moderate-to-severe ARDS, informing NMBA choice beyond cisatracurium. An ELSO registry analysis reported 72.3% survival to discharge for ECMO after lung transplant with increasing use and improving survival trends. A correction notice alerts readers to updates in a major comparative study of COVID-19 ARDS versus pre-COVID pneumonia ARDS.
Summary
Among today's ARDS-focused papers, a national cohort study found no outcome advantage with continuous rocuronium in moderate-to-severe ARDS, informing NMBA choice beyond cisatracurium. An ELSO registry analysis reported 72.3% survival to discharge for ECMO after lung transplant with increasing use and improving survival trends. A correction notice alerts readers to updates in a major comparative study of COVID-19 ARDS versus pre-COVID pneumonia ARDS.
Research Themes
- Neuromuscular blockade strategies in ARDS
- ECMO utilization and outcomes in post–lung transplant respiratory failure
- Post-publication corrections in ARDS epidemiology and ventilation management research
Selected Articles
1. Extracorporeal membrane oxygenation after lung transplant: An ELSO registry analysis.
In a 2010–2022 ELSO registry analysis of 1,966 adults receiving ECMO >24 hours after lung transplant, 72.3% survived to discharge. ECMO use increased over time with a trend toward improved survival, and higher annual center volume was identified as a predictor in adjusted models.
Impact: Provides contemporary, large-scale, multicenter outcomes for ECMO after lung transplant and highlights a potential volume–outcome relationship, informing program design and benchmarking.
Clinical Implications: Supports referral to experienced centers and informs expectations for survival after ECMO in post–lung transplant respiratory failure; may guide resource allocation and quality metrics.
Key Findings
- Among 1,966 ECMO runs >24 hours after lung transplant, 72.3% of patients survived to discharge.
- ECMO utilization increased steadily across 2010–2022, with a trend toward improving survival.
- Multivariable logistic regression identified center-level factors, including higher annual center volume (reported OR 0.97 in excerpt), as predictors of survival.
Methodological Strengths
- Large, international registry with multi-year coverage
- Multivariable modeling to identify predictors of survival
Limitations
- Observational registry design with potential residual confounding and selection bias
- Abstract excerpt is truncated; full list of predictors and effect sizes not available here
Future Directions: Define center-level best practices and minimum volume thresholds; link registry with granular clinical and ECMO configuration data to refine risk models.
BackgroundThe use of extracorporeal membrane oxygenation (ECMO) has expanded and is now widely applied to perioperative care in lung transplant. Respiratory failure after lung transplant is a clinical challenge where ECMO plays a critical role.MethodsThe Extracorporeal Life Support Organization registry was queried for patients 18 years and older who were treated with ECMO after lung transplant in 2010-2022. ECMO runs for more than 24 hours after lung transplant were included regardless of the timing of initiation. Univariable analyses were performed to compare procedural and patient characteristics across ECMO eras. Multivariable logistic regression was performed to identify predictors of surviving to discharge.ResultsOne-thousand nine-hundred and sixty-six patients met the inclusion criteria, and 1422 patients (72.3%) survived to discharge. The number of ECMO runs steadily increased throughout the study period, with a trend of improving survival. Higher annual center volume (Odds Ratio[OR]: 0.97,
2. Association Between Rocuronium Administration and Clinical Outcomes in Patients With Moderate-To-Severe Acute Respiratory Distress Syndrome: A Retrospective Cohort Study.
In a national retrospective cohort of 1,992 ICU patients with pneumonia and moderate-to-severe ARDS (respiratory SOFA ≥3), continuous rocuronium infusion was not associated with differences in in-hospital or ICU mortality, length of stay, or duration of mechanical ventilation. Findings support rocuronium as a feasible alternative NMBA without observed harm.
Impact: Addresses a clinically relevant gap regarding non-cisatracurium NMBA use in ARDS, providing real-world evidence to guide sedo-analgesia and ventilatory synchronization strategies.
Clinical Implications: Rocuronium may be used as a continuous NMBA option for ventilator management in moderate-to-severe ARDS without expectation of improved mortality; selection should consider patient-specific factors and warrants prospective evaluation.
Key Findings
- Among 1,992 eligible ICU patients with moderate-to-severe ARDS due to pneumonia, 124 (6.2%) received continuous rocuronium.
- No significant difference in in-hospital mortality (OR 0.70; 95% CI 0.42–1.19) or ICU mortality (OR 0.87; 95% CI 0.41–1.87) between exposure and comparison groups.
- No significant differences in hospital length of stay, ICU stay, or duration of mechanical ventilation based on adjusted models with generalized estimating equations.
Methodological Strengths
- Nationwide inpatient database with clearly defined inclusion criteria
- Multivariable regression using generalized estimating equations to account for clustering
Limitations
- Retrospective observational design with potential confounding by indication
- Small exposure group (n=124) and limited detail on dosing, timing, and sedation practices
Future Directions: Prospective trials comparing rocuronium vs. cisatracurium with protocolized sedation and ventilatory targets; subgroup analyses by ARDS severity and ventilator asynchrony.
BACKGROUND: Neuromuscular blocking agents (NMBAs) are commonly used to manage acute respiratory distress syndrome (ARDS). However, the efficacy of continuous NMBA administration other than cisatracurium remains understudied. OBJECTIVE: To examine the association between continuous rocuronium administration and clinical outcomes in patients with moderate-to-severe ARDS. METHODS: A retrospective cohort study was performed using data from a Japanese national inpatient database (April 2018-March 2022). Adult patients with pneumonia requiring mechanical ventilation in the intensive care unit (ICU), with respiratory Sequential Organ Failure Assessment score of ≥3 were included. The patients were divided into those receiving continuous rocuronium (exposure group) and those not receiving any continuous NMBAs (comparison group). The association between continuous rocuronium administration and outcomes was analyzed using multivariable regression analyses fitted with generalized estimating equations. RESULTS: Among 1992 eligible patients, 124 received rocuronium. In-hospital mortality were 30.8% and 25.8% in the comparison and exposure groups, respectively. No significant differences observed in in-hospital mortality (odds ratio [OR] 0.70; 95% confidence interval [CI]: 0.42 to 1.19), ICU mortality (9.0% vs 8.9%, OR 0.87; 95% CI: 0.41 to 1.87), median length of hospital stay (26 vs 28 days, %change 10.5; 95% CI: -8.9 to 34.1), ICU stay (8 vs 10 days, %change 9.0; 95% CI: -4.3 to 24.2), or mechanical ventilation (7 vs 10 days, %change 10.3; 95% CI: -5.3 to 28.5). CONCLUSION AND RELEVANCE: Continuous rocuronium administration for moderate-to-severe ARDS, specifically in patients with pneumonia, was not associated with either improved or worsened clinical outcomes. These findings suggest that rocuronium may be a feasible option as a supportive therapy for ventilator management in patients with moderate-to-severe ARDS, providing a basis for further research in clinical settings.
3. Correction to: Epidemiology, ventilation management and outcomes of COVID-19 ARDS patients versus patients with ARDS due to pneumonia in the Pre-COVID era.
This is a correction notice for a comparative study on epidemiology, ventilation management, and outcomes of COVID-19 ARDS versus pre-COVID pneumonia-related ARDS. No abstract text is provided in the record.
Impact: Signals post-publication updates to a widely relevant ARDS comparison, maintaining scientific record integrity.
Clinical Implications: Clinicians and researchers should consult the correction alongside the original article to ensure accurate interpretation of methods and outcomes.
Key Findings
- This publication is a correction notice linked to a study comparing COVID-19 ARDS with pre-COVID pneumonia-related ARDS.
- The record provides no abstract and does not present new analyses or data in this notice.
- Readers are alerted that aspects of the original report have been corrected; specifics must be obtained from the correction text.
Methodological Strengths
- Transparent post-publication correction process
- Supports accuracy and reproducibility by updating the scientific record
Limitations
- No abstract or detailed correction content provided in the record
- No new methodological or outcome data presented
Future Directions: Assess whether corrections materially affect conclusions; if substantial, consider sensitivity analyses or updated meta-analyses incorporating the corrected data.